2023 World Conference on Lung Cancer (Posters)-EP13.06. Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer

EP13.06. Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a presentation titled "Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer" at the WCLC 2023 conference. The study aims to evaluate the efficacy and safety of a combination treatment for extensive-stage small-cell lung cancer (ES-SCLC).<br /><br />The study builds upon previous research showing that the addition of immune checkpoint inhibitors (ICI) to existing chemotherapy treatments for ES-SCLC can significantly improve progression-free survival (PFS) and overall survival (OS). The researchers aim to further enhance these results by including plinabulin, a synthetic analogue of a chemical found in a marine fungus, which has immune-enhancing effects and can prevent chemotherapy-induced neutropenia.<br /><br />The study is an open-label, single-arm, phase II trial, which means that all participants will receive the same treatment. Approximately 45 patients with histologically confirmed ES-SCLC, who have not undergone prior systemic therapy, will be enrolled. The treatment regimen includes pembrolizumab, etoposide, platinum, and plinabulin administered in cycles.<br /><br />The primary endpoint of the study is the PFS rate at 12 months. Secondary endpoints include the objective response rate, duration of response, median PFS, OS, and safety. The study will also include a safety run-in period to closely monitor the occurrence of adverse events during the first 21 days of treatment.<br /><br />This study has been approved by the hospital institutional review board and is categorized under the track of Small Cell Lung Cancer and Neuroendocrine Tumors at the conference. It falls under the Clinical Trials in Progress abstract type.<br /><br />Overall, this study aims to assess the effectiveness and safety of combining pembrolizumab, plinabulin, etoposide, and platinum as a first-line therapy for ES-SCLC patients and potentially improve outcomes for this patient population.

Asset Subtitle

Xiaorong Dong

Meta Tag

Speaker Xiaorong Dong

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

Phase II Study

Pembrolizumab

Plinabulin

Etoposide

Platinum

First-Line Therapy

Extensive-Stage Small-Cell Lung Cancer

Efficacy

Safety

Combination Treatment